Aryplase: BMRN began an open-label international Phase II trial of Aryplase given as a 1 mg/kg weekly intravenous infusion in 10 MPS-IV patients.

BioMarin Pharmaceutical Inc. (BMRN; SWX:BMRN), Novato, Calif. Product: Aryplase ( rhASB) Business: Metabolic Therapeutic category: Metabolism, Enzyme replacement Target: Lysosomal carbohydrates Descr...